AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/10/22

Aurinia Pharma press release (NASDAQ:AUPH): Q1 GAAP EPS of -$0.27 in-line. Revenue of $21.63M (+2276.9% Y/Y) beats by $2.39M. The company maintains net revenue guidance range of $115M-$135M from sales of LUPKYNIS for 2022 vs. consensus of $138.01M. For further details see: Aurinia Pharm...

$21.6 million in net revenue for Q1 2022; Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS for 2022 Continued increases in LUPKYNIS™ (voclosporin) Patients on Treatment and Patient Start Forms; Steady Conversion Rates and Payor Coverage ...

Aurinia Pharma (NASDAQ:AUPH) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$0.27 (+32.5% Y/Y) and the consensus Revenue Estimate is $19.24M (+2014.3% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revision...

ACRS, AFCG, AGEN, AHCO, ALGM, AMRS, ANIP, ARMK, AROC, ARVL, ATNX, AUPH, AVYA, AZEK, OTCPK:BAYZF, BCO, BHC, BLDE, BLDR, BSY, CCO, CEVA, CHH, CMPS, CRNC, CRON, DBD, DCTH, DM, DS, EBIX, ENOV, EOSE, EPC, EPZM, EVRI, FOX, FOXA, GMDA, H, HAE, HL, IAA, IGT, IIVI, IMUX, ITCI, JAGX, OTCPK:KEYUF, KNBE,...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter financial and operational results announcement on Tuesday, May 10, 2022. The new numbers for interested partici...

New York, New York--(Newsfile Corp. - May 6, 2022) - Levi & Korsinsky, LLP notifies investors in Aurinia Pharmaceuticals Inc. ("Aurinia Pharmaceuticals Inc." or the "Company") (NASDAQ: AUPH) of a class action securities lawsuit. The lawsuit on behalf of Aurinia Pharmaceuticals Inc. inve...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022, before markets open. Aurinia’s management team will host a ...

Do you like stocks with triple-digit revenue growth? Here are three companies you might want to dig into. First up is Outset Medical (NASDAQ: OM) , a healthcare company that doubled its sales last year. The next one is Aurinia Pharmaceuticals (NASDAQ: AUPH) ; analysts ar...

The shares of Canadian biotech Aurinia Pharmaceuticals (NASDAQ:AUPH) are trading lower in the morning hours Thursday after RBC Capital Markets lowered its price target, citing Omicron-driven impact for sales of the company’s lupus nephritis therapy, Lupkynis. Ahead of Aurinia’s ...

– Company seeks proposals to create and sustain community-focused programs to support underserved populations with these conditions – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today, affirmed its commitment to individuals livi...